CoRegen Appoints Globally Recognized Surgeon-Scientist Bert O’Malley Jr. to its Board of Directors

HOUSTON, Dec. 22, 2025 (GLOBE NEWSWIRE) -- CoRegen, Inc., a biopharmaceutical company pursuing novel treatments for patients impacted by some of the most aggressive forms of solid tumor cancer, today ...
CURE

Navigating Your Stage 3 Renal Cell Carcinoma Diagnosis

Symptoms of stage 3 RCC vary; some patients experience blood in the urine, flank pain, fatigue, weight loss, or a palpable ...